Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

The award carries a $7.93 exercise price and vests in stages subject to the employee’s continued service.

Rhea-AI Summary

Bicara Therapeutics (Nasdaq: BCAX) awarded a new employee an inducement stock option covering 50,000 shares on November 2, 2026.

The $7.93 per-share exercise price equals the Nasdaq closing price that day. One-fourth of the options vest on the first anniversary of the employee’s applicable start date; the remainder vest in 12 equal quarterly installments, subject to continued service through each vesting date. The compensation committee approved the award under the 2026 Inducement Plan, outside stockholder-approved equity incentive plans, in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 50,000 shares at a $7.93 exercise price create potential dilution upon exercise.

Key Figures

Options granted: 50,000 shares Exercise price: $7.93 per share Initial vesting: One-fourth +1 more

Options granted

50,000 shares

Inducement award to one new employee

Exercise price

$7.93 per share

Equal to the November 2, 2026 Nasdaq closing price

Initial vesting

One-fourth

Vests on the first anniversary of the employee’s applicable start date

Remaining vesting

12 equal quarterly installments

Subject to continued service through each vesting date

Key Terms

non-qualified stock option, nasdaq listing rule 5635(c)(4)

2 terms

non-qualified stock option financial

"The employee received a non-qualified stock option to purchase 50,000 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on November 2, 2026, to one new employee as a material inducement to employment under Bicara’s 2026 Inducement Plan.

The employee received a non-qualified stock option to purchase 50,000 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $7.93 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on November 2, 2026. One-fourth of the options vest on the first anniversary of the employee’s applicable start date, with the remaining options vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date.

The above award was granted outside of Bicara’s stockholder-approved equity incentive plans and is pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The award was approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).

About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors
Rachel Frank
IR@bicara.com

Media
Tim Palmer
Tim.Palmer@bicara.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock option did Bicara Therapeutics grant its new employee?

Bicara awarded an option to purchase 50,000 common shares at $7.93 per share on November 2, 2026. The exercise price equals the Nasdaq closing price that day.

When does Bicara Therapeutics’ employee inducement option vest?

One-fourth vests on the first anniversary of the employee’s applicable start date, and the remainder vests in 12 equal quarterly installments thereafter. Vesting requires continued service through each applicable vesting date.